Linked Life Data

3721185

Source:http://linkedlifedata.com/resource/pubmed/id/3721185

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1986-7-25
pubmed:abstractText
The interaction between ergotamine 3 and 30 micrograms/kg i.v. and darodipine (PY108-068) 30 micrograms/kg i.v. was studied in anaesthetized cats. Ergotamine decreased heart rate, cardiac output and total peripheral conductance dose-dependently. Ergotamine caused regional vasoconstriction (measured with tracer microspheres) in the heart, kidneys, adrenals, liver, spleen, skin and arterio-venous shunts but dilatation in the pancreas and skeletal muscle, possibly attributable to serotoninergic stimulation. Darodipine reversed most ergotamine effects except those on the spleen, skin and arterio-venous shunts. Since constriction of arterio-venous shunts was not inhibited, ergotamine is unlikely to lose its effectiveness in migraine patients under concomitant dihydropyridine treatment, while unwanted vasoconstrictor effects are likely to be diminished.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0306-3623
pubmed:author
pubmed:issnType
Print
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
309-14
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1986
pubmed:articleTitle
Mutual inhibition and synergistic effects of ergotamine and the calcium antagonist darodipine.
pubmed:publicationType
Journal Article